Nabiha Saklayen, Cellino co-founder and CEO (via Cellino)

Backed by Bay­er's Leaps, Boston-based Celli­no lands $80M for cell ther­a­py-in-box

The sum­mer be­fore Celli­no CEO and co-founder Nabi­ha Sak­layen start­ed at Har­vard, she lost her grand­moth­er fol­low­ing com­pli­ca­tions to di­a­betes. Be­fore then, she hadn’t tak­en a bi­ol­o­gy class since ninth or tenth grade — the mark of a clas­sic physi­cist — but it was then she de­cid­ed she want­ed the rest to sit at the in­ter­sec­tion of the two for the rest of her ca­reer.

Com­bine that with be­ing across the way from the Uni­ver­si­ty’s stem cell in­sti­tute in Cam­bridge, and you get the birth of Celli­no, an au­tonomous cell ther­a­py man­u­fac­tur­ing com­pa­ny that just an­nounced the clos­ing of its Se­ries A.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.